1 Stoll S, Unger S, Azzarello-Burri S, Chappuis P, Graffeo R, Pichert G, et al. Update Swiss guideline for counselling and testing for predisposition to breast, ovarian, pancreatic and prostate cancer. Swiss Med Wkly. 2021;151:w30038.
2 Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375(5):443–53.
3 Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Survival with Olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020;383(24):2345–57.
4 Daly MB, Pilarski R, Yurgelun MB, Berry MP, Buys SS, Dickson P, et al. NCCN guidelines insights: Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic. Version 1.2020. J Natl Compr Canc Netw. 2020;18(4):380–91.
5 Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, et al. Role of genetic testing for inherited prostate cancer risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018;36(4):414–24.
6 Chappuis PO, Bolliger B, Bürki N, Buser K, Heinimann K, Monnerat C, et al. Swiss guidelines for counseling and testing. Genetic predisposition to breast and ovarian cancer. Swiss Group for Clinical Cancer Research (SAKK). 2018; online unter:
https://www.sakk.ch/sites/default/files/2018-11/Swiss_guidelines_for_counseling_and_testing_for_genetic_predisposition_to_breast_and_ovarian_cancer.pdf; letzter Aufruf am 23.10.2021.
7 Schweizerischen Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK). Genetische Beratung; Zentren der Schweiz. Online unter:
https://www.sakk.ch/de/fuer-patienten/genetische-beratung; letzter Aufruf am 23.10.2021.